RecruitingNCT06642831

Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study

Polycystic Ovarian Syndrome (PCOS) in Human Adolescent and Young Adult Females - Biomarker Evaluation Study (PHOEBE)


Sponsor

University Hospital Erlangen

Enrollment

380 participants

Start Date

Jan 31, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.


Eligibility

Sex: FEMALEMin Age: 15 YearsMax Age: 25 Years

Inclusion Criteria2

  • Female subjects age 15-25 years
  • Signed written informed consent

Exclusion Criteria5

  • Less than 1 years from onset of menarche
  • Use of hormonal contraceptives
  • Documented ongoing pregnancy
  • Major ovarian abnormalities, including subject with only one ovary, cysts and solid masses \> 2 cm as detected by transvaginal ultrasound
  • Malignancy ( documented malignancy, documentation of current radiation therapy or chemotherapy in medical record)

Locations(1)

Department of Obstetrics and Gynecology, University Erlangen Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany

Erlangen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06642831


Related Trials